专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090149467A1 Tyrosine Kinase Inhibitors 审中-公开
标题翻译：酪氨酸激酶抑制剂
公开(公告)号：US20090149467A1
公开(公告)日：2009-06-11
申请号：US11991862
申请日：2006-09-11
申请人： Christopher J. Dinsmore , David J. Guerin , Barbara Hanney , Yuntae Kim , Keith L. Spencer , Maricel Torrent
发明人： Christopher J. Dinsmore , David J. Guerin , Barbara Hanney , Yuntae Kim , Keith L. Spencer , Maricel Torrent
IPC分类号： A61K31/506 , C07D403/12 , C07D401/14 , A61P35/00 , C07D401/12 , C07D487/04
CPC分类号： C07D403/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D487/04
摘要： The present invention relates to pyridinyloxy- and pyrimidinyloxyindole derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
摘要翻译：本发明涉及可用于治疗细胞增殖性疾病的吡啶氧基 - 和嘧啶氧基吲哚衍生物，用于治疗与MET活性相关的疾病，以及用于抑制受体酪氨酸激酶MET。本发明还涉及包含这些化合物的组合物，以及使用它们治疗哺乳动物癌症的方法。

2. 发明授权

US07622592B2 Carbonylamino-benzimidazole derivatives as androgen receptor modulators 失效
标题翻译：羰基氨基 - 苯并咪唑衍生物作为雄激素受体调节剂
公开(公告)号：US07622592B2
公开(公告)日：2009-11-24
申请号：US10533259
申请日：2003-10-28
申请人： Yuntae Kim , Barbara Hanney , Mark E. Duggan , Keith L. Spencer
发明人： Yuntae Kim , Barbara Hanney , Mark E. Duggan , Keith L. Spencer
IPC分类号： A61K31/427 , C07D417/04
CPC分类号： C07D417/04 , C07D401/04 , C07D403/04 , C07D417/14
摘要： Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
摘要翻译：结构式（I）的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。它们可用作骨和/或肌肉组织中雄激素受体的激动剂，同时拮抗男性患者的前列腺中或在女性患者的子宫中的AR。因此，这些化合物可用于增强减弱的肌肉紧张度和治疗由雄激素缺乏引起的或由雄激素给药引起的疾病的治疗，包括骨质疏松症，骨质减少症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨骼骨损伤重建手术，肌肉减少症，脆弱性，皮肤老化，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，关节炎病症和关节修复，艾滋病毒消耗，前列腺癌，癌症恶病质，阿尔茨海默病疾病，肌营养不良，卵巢早衰，自身免疫疾病，单独或与其他活性剂组合。

3. 发明授权

US07101884B2 Tyrosine kinase inhibitors 失效
公开(公告)号：US07101884B2
公开(公告)日：2006-09-05
申请号：US10489594
申请日：2002-09-10
申请人： Kenneth L. Arrington , Mark E. Fraley , Barbara Hanney , Yuntae Kim , Keith L. Spencer
发明人： Kenneth L. Arrington , Mark E. Fraley , Barbara Hanney , Yuntae Kim , Keith L. Spencer
IPC分类号： C07D403/04 , C07D403/14 , A61K31/416 , A61K31/4162
CPC分类号： C07D401/14 , C07D401/04 , C07D403/04 , C07D403/14 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

4. 发明授权

US07186723B2 Tyrosine kinase inhibitors 失效
公开(公告)号：US07186723B2
公开(公告)日：2007-03-06
申请号：US10487589
申请日：2002-08-26
申请人： Jennifer P. Peckham , William F. Hoffman , Kenneth L. Arrington , Mark E. Fraley , George D. Hartman , Yuntae Kim , Barbara Hanney , Keith L. Spencer
发明人： Jennifer P. Peckham , William F. Hoffman , Kenneth L. Arrington , Mark E. Fraley , George D. Hartman , Yuntae Kim , Barbara Hanney , Keith L. Spencer
IPC分类号： C07D241/04 , A61K31/4965
CPC分类号： C07D417/14 , C07D401/04 , C07D401/14
摘要： The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

5. 发明授权

US06927293B2 Tyrosine kinase inhibitors 失效
公开(公告)号：US06927293B2
公开(公告)日：2005-08-09
申请号：US10487588
申请日：2002-08-26
申请人： Yuntae Kim , Barbara Hanney , Keith L. Spencer , George D. Hartman , Kenneth L. Arrington
发明人： Yuntae Kim , Barbara Hanney , Keith L. Spencer , George D. Hartman , Kenneth L. Arrington
IPC分类号： A61K31/4709 , C07D401/04 , C07D401/14 , A61K31/44 , C07D453/02 , C07D47/02
CPC分类号： C07D401/04 , A61K31/4709 , C07D401/14
摘要： The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

6. 发明申请

US20100267633A1 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators 审中-公开
标题翻译： N-（4-氧代-3,4-二氢喹唑啉-2-基）丁酰胺作为雄激素受体调节剂
公开(公告)号：US20100267633A1
公开(公告)日：2010-10-21
申请号：US11992446
申请日：2006-09-22
申请人： Barbara Hanney , Yuntae Kim , Helen J. Mitchell , Jeffrey D. Musselman , James J. Perkins
发明人： Barbara Hanney , Yuntae Kim , Helen J. Mitchell , Jeffrey D. Musselman , James J. Perkins
IPC分类号： A61K31/517 , C07D239/72 , A61K31/565 , A61K38/27 , A61K38/29 , A61K38/18 , A61K31/59 , A61P19/10 , A61P19/00 , A61P21/00 , A61P1/02 , A61P17/00 , A61P15/08 , A61P25/00 , A61P9/10 , A61P7/00 , A61P3/04 , A61P19/02 , A61P31/18 , A61P35/00 , A61P25/28 , A61P15/00 , A61P11/00 , A61P3/10 , A61P3/00 , A61P25/24 , A61P37/00 , A61K31/663 , A61K38/23 , A61K38/30 , A61K38/14
CPC分类号： C07D403/06 , C07D239/90 , C07D409/12
摘要： The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia.
摘要翻译：本发明涉及调节雄激素受体以治疗诸如骨质疏松症，肠周周疾病，骨折，虚弱和肌肉减少症之类的病症的取代的N-（4-氧代-3,4-二氢喹唑啉-2-基）丁酰胺衍生物。

7. 发明授权

US07268153B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators 失效
标题翻译： N-（2-苄基）-2-苯基丁酰胺作为雄激素受体调节剂
公开(公告)号：US07268153B2
公开(公告)日：2007-09-11
申请号：US11145490
申请日：2005-06-03
申请人： Barbara Hanney , Yuntae Kim , Michael R. Krout , Robert S. Meissner , Helen J. Mitchell , Jeffrey Musselman , James J. Perkins , Jiabing Wang
发明人： Barbara Hanney , Yuntae Kim , Michael R. Krout , Robert S. Meissner , Helen J. Mitchell , Jeffrey Musselman , James J. Perkins , Jiabing Wang
IPC分类号： A61K31/165
CPC分类号： C07D295/205 , C07C233/13 , C07C235/34 , C07C255/60 , C07C271/12 , C07C271/22 , C07C2601/02 , C07D213/61 , C07D213/73
摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
摘要翻译：结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

8. 发明授权

US07629367B2 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators 失效
标题翻译： N-（2-苄基）-2-苯基丁酰胺作为雄激素受体调节剂
公开(公告)号：US07629367B2
公开(公告)日：2009-12-08
申请号：US11628685
申请日：2005-06-03
申请人： Barbara Hanney , Yuntae Kim , Michael R. Krout , Robert S. Meissner , Helen J. Mitchell , Jeffrey Musselman , James J. Perkins , Jiabing Wang
发明人： Barbara Hanney , Yuntae Kim , Michael R. Krout , Robert S. Meissner , Helen J. Mitchell , Jeffrey Musselman , James J. Perkins , Jiabing Wang
IPC分类号： A61K31/165
CPC分类号： C07D295/205 , C07C233/13 , C07C235/34 , C07C255/60 , C07C271/12 , C07C271/22 , C07C2601/02 , C07D213/61 , C07D213/73
摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
摘要翻译：结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。这些化合物可用于增强减弱的肌肉紧张度和治疗由雄激素缺乏引起的或由雄激素施用引起的疾病的治疗，包括骨质疏松症，骨质减少症，糖皮质激素诱导的骨质疏松症，牙周病骨折，骨重建手术后的骨损伤，肌肉减少症，虚弱，老化的皮肤，男性性腺机能减退，妇女绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎症性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生症（BPH），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰，以及自身免疫疾病，单独或与其他活性剂组合。

9. 发明申请

US20050070546A1 Tyrosine kinase inhibitors 失效
公开(公告)号：US20050070546A1
公开(公告)日：2005-03-31
申请号：US10489594
申请日：2002-09-10
申请人： Kenneth Arrington , Mark Fraley , Barbara Hanney , Yuntae Kim , Keith Spencer
发明人： Kenneth Arrington , Mark Fraley , Barbara Hanney , Yuntae Kim , Keith Spencer
IPC分类号： A61K31/519 , A61P9/10 , A61P35/00 , C07D401/14 , C07D403/04 , C07D403/14 , C07D471/04 , C07D487/02 , C07D487/04
CPC分类号： C07D401/14 , C07D401/04 , C07D403/04 , C07D403/14 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

10. 发明申请

US20090088458A1 N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators 审中-公开
标题翻译： N-（吡啶-4-基）-2-苯基丁酰胺作为雄激素受体调节剂
公开(公告)号：US20090088458A1
公开(公告)日：2009-04-02
申请号：US11989412
申请日：2006-07-28
申请人： Robert S. Meissner , James J. Perkins , Yuntae Kim , Barbara Hanney , Carol A. McVean
发明人： Robert S. Meissner , James J. Perkins , Yuntae Kim , Barbara Hanney , Carol A. McVean
IPC分类号： A61K31/4418 , C07D213/36 , A61P19/02 , A61K38/27 , C07D213/63
CPC分类号： C07D213/61 , A61K31/44 , C07D213/64 , C07D213/65 , Y02A50/401
摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
摘要翻译：结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式